AQST - アクエスティブ・セラピュ―ティクス (Aquestive Therapeutics Inc.) アクエスティブ・セラピュ―ティクス

 AQSTのチャート


 AQSTの企業情報

symbol AQST
会社名 Aquestive Therapeutics Inc (アクエスティブ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Aquestive Therapeutics Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant Sympazan and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108 and AQST-305 for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs which includes Suboxone and APL-130277 for the treatment of opioid dependence and Parkinson’s disease.   アクエスティブ・セラピュ―ティクスは米国の特殊医薬品企業。主に満たされていない医療ニ―ズに焦点を当て、製品の特定や開発、商業化に従事する。同社の「PharmFilm」は既存の処方薬を直接血流に送達するプラットフォ―ム医薬製剤。医薬品フィルム、個別使用フィルム、患者・医師・介護用のフィルムなどを製造する。本社所在地はニュ―ジャ―ジ―州ウォ―レン。   
本社所在地 30 Technology Drive Warren NJ 07059 USA
代表者氏名
代表者役職名
電話番号 +1 908-941-1900
設立年月日 37987
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 195人
url www.aquestive.com
nasdaq_url https://www.nasdaq.com/symbol/aqst
adr_tso
EBITDA EBITDA(百万ドル) -20.56200
終値(lastsale) 15.775
時価総額(marketcap) 393203343.425
時価総額 時価総額(百万ドル) 369.13940
売上高 売上高(百万ドル) 76.67900
企業価値(EV) 企業価値(EV)(百万ドル) 404.93140
当期純利益 当期純利益(百万ドル) -35.23500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aquestive Therapeutics Inc revenues increased 35% to $37.3M. Net loss applicable to common stockholders increased from $8.6M to $32.4M. Revenues reflect United States segment increase of 46% to $23.2M Malaysia segment increase of 22% to $33K. Higher net loss reflects Selling General and administrative increase from $10.6M to $41.2M (expense) Research_Development increase of 18% to $12.9M (expense).

 AQSTのテクニカル分析


 AQSTのニュース

   Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment  2021/01/21 13:30:00 PR Newswire
JERSEY CITY, N.J. and WARREN, N.J., Jan. 21, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S. rights to commercialize EXSERVAN™ (riluzole), an oral film formulation…
   Aquestive Therapeutics Provides Business Update  2021/01/07 12:30:00 GlobeNewswire
Resubmitted revised dosing regimen for Libervant to FDA in December 2020, as committedMultiple clinical trials demonstrate that AQST-108 can consistently…
   Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/25 14:15:00 GlobeNewswire
WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and…
   Aquestive Therapeutics gets pathway for Libervant FDA resubmission (NASDAQ:AQST)  2020/11/18 21:49:44 Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) +11.6% after-hours as it completed its Type A meeting with the Food and Drug Administration confirming a pathway for r
   Aquestive Therapeutics Analysts Estimate Report : What to Look Out for Stock market Insights & financial analysis  2020/11/04 21:31:00 Stock Market Daily
Aquestive Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment  2021/01/21 13:30:00 PR Newswire
JERSEY CITY, N.J. and WARREN, N.J., Jan. 21, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S. rights to commercialize EXSERVAN™ (riluzole), an oral film formulation…
   Aquestive Therapeutics Provides Business Update  2021/01/07 12:30:00 GlobeNewswire
Resubmitted revised dosing regimen for Libervant to FDA in December 2020, as committedMultiple clinical trials demonstrate that AQST-108 can consistently…
   Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/25 14:15:00 GlobeNewswire
WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and…
   Aquestive Therapeutics gets pathway for Libervant FDA resubmission (NASDAQ:AQST)  2020/11/18 21:49:44 Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) +11.6% after-hours as it completed its Type A meeting with the Food and Drug Administration confirming a pathway for r
   Aquestive Therapeutics Analysts Estimate Report : What to Look Out for Stock market Insights & financial analysis  2020/11/04 21:31:00 Stock Market Daily
Aquestive Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment  2021/01/21 13:30:00 PR Newswire
JERSEY CITY, N.J. and WARREN, N.J., Jan. 21, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S. rights to commercialize EXSERVAN™ (riluzole), an oral film formulation…
   Aquestive Therapeutics Provides Business Update  2021/01/07 12:30:00 GlobeNewswire
Resubmitted revised dosing regimen for Libervant to FDA in December 2020, as committedMultiple clinical trials demonstrate that AQST-108 can consistently…
   Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/25 14:15:00 GlobeNewswire
WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and…
   Aquestive Therapeutics gets pathway for Libervant FDA resubmission (NASDAQ:AQST)  2020/11/18 21:49:44 Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) +11.6% after-hours as it completed its Type A meeting with the Food and Drug Administration confirming a pathway for r
   Aquestive Therapeutics Analysts Estimate Report : What to Look Out for Stock market Insights & financial analysis  2020/11/04 21:31:00 Stock Market Daily
Aquestive Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

 関連キーワード  (医薬品 米国株 アクエスティブ・セラピュ―ティクス AQST Aquestive Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)